guestts

Guestts

From USD 5.5 billion in 2024, the Autologous Stem Cell & Non-stem Cell Therapies Market is forecasted to surge to USD 22.2 billion by 2029, growing at a 32.3% CAGR. This increase is attributed to rising regulatory approvals for therapies such as CAR-T and TIL, coupled with significant R&D investments.

Autologous non-stem cell therapies accounted for the largest share of the type segment in 2023.

Autologous non-stem cell therapies are an important sub-segment in the autologous stem cell & non-stem cell therapies market for type segment. This sub-segment accounted for the largest market share of the autologous stem cell & non-stem cell therapies market. This large share of the autologous non-stem cell therapies sub-segment can be attributed to the rising approvals for CAR T cell therapies and the growing incidence of global cancer cases which is impacting millions of individuals, increasing the demand for the development of effective treatment options such as autologous CAR T cell therapies.

Cancer Indications accounted for the largest share of the indication segment in the autologous stem cell & non-stem cell therapies market in 2023.

By indication, the autologous stem cell & non-stem cell therapies market is divided into cancer, musculoskeletal, dermatology, and other indications such as autoimmune disorders, spinal cord injuries, and ocular defects, among others.

 Cancer Indications accounted for the largest share of the autologous stem cell & non-stem cell therapies market in 2023. The large share of this market is attributed to factors such as the increasing number of global cancer cases resulting in a rising demand for cancer therapeutics, and ongoing R&D to develop more effective therapies for the treatment of various forms of cancer including solid tumors.

The hospitals and clinics subsegment accounted for the largest share of the end user segment in the autologous stem cell & non-stem cell therapies market in 2023.

In 2023, hospitals and clinics accounted for the largest share of the end-user segment of the autologous stem cell & non-stem cell therapies market. The largest share is due to the increasing number of regulatory approvals for autologous non-stem cell therapies for the treatment of various forms of cancer and other chronic diseases. The increasing global burden of cancer has propelled the development of novel therapies to combat these diseases. Hospitals provide the infrastructure for apheresis, the process of collecting cells from the patient. This procedure is crucial for developing autologous cell therapies, as it ensures the quality and viability of the cells to be used. Biopharmaceutical firms continuously partner with hospitals to streamline the process, ensuring that patients receive treatments promptly and efficiently.

North America to register the highest CAGR in the autologous stem cell & non-stem cell therapies market.

The North American region is expected to register the highest CAGR of the autologous stem cell & non-stem cell therapies market. The rising investments for autologous stem cell and non-stem cell-based research, expansion of the healthcare sector, growing cancer prevalence, and the increasing approval and adoption of autologous stem cell and non-stem cell-based therapies for treating cancer and other chronic diseases are expected to aid market growth in North America.

Some leading players operating in the autologous stem cell & non-stem cell therapies market are Gilead Sciences, Inc. (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Vericel Corporation (US), Novartis AG (Switzerland), JW (Cayman) Therapeutics Co. Ltd (China), Iovance Biotherapeutics, Inc. (US), APAC Biotech (India), Regrow Biosciences Pvt Ltd. (India), healiva SA (Switzerland), Green Cross Holdings Co., Ltd. (GC Cell) (Republic of Korea), Sanpower Group Co., Ltd. (Dendreon Pharmaceuticals Llc. (China), Tegoscience (South Korea), ImmunoACT (India), CARsgen Therapeutics Holdings Limited (China), IASO Biotherapeutics (China), Pharmicell Co., Ltd (South Korea), Anterogen.Co., Ltd. (South Korea)

About MarketsandMarketsâ„¢:

MarketsandMarketsâ„¢ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarketsâ„¢ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStoreâ„¢ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Rohan Salgarkar
MarketsandMarketsâ„¢ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/

Leave a Reply

Your email address will not be published. Required fields are marked *